On Monday, Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) opened higher 8.26% from the last session, before settling in for the closing price of $22.51. Price fluctuations for RARE have ranged from $18.41 to $46.50 over the past 52 weeks.
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 2.45%. Company’s average yearly earnings per share was noted 10.12% at the time writing. With a float of $89.78 million, this company’s outstanding shares have now reached $96.27 million.
Ultragenyx Pharmaceutical Inc (RARE) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Ultragenyx Pharmaceutical Inc is 6.94%, while institutional ownership is 98.94%. The most recent insider transaction that took place on Jan 02 ’26, was worth 71,946. In this transaction Chief Financial Officer of this company sold 3,150 shares at a rate of $22.84, taking the stock ownership to the 91,996 shares. Before that another transaction happened on Jan 02 ’26, when Company’s Officer proposed sale 3,150 for $22.84, making the entire transaction worth $71,946.
Ultragenyx Pharmaceutical Inc (RARE) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -1.39 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -1.27) by -0.12. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.42 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 10.12% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 39.90% during the next five years compared to 2.45% growth over the previous five years of trading.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Trading Performance Indicators
Check out the current performance indicators for Ultragenyx Pharmaceutical Inc (RARE). In the past quarter, the stock posted a quick ratio of 1.74. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.73.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.94, a number that is poised to hit -1.15 in the next quarter and is forecasted to reach -3.83 in one year’s time.
